2019 saw fewer revenues-boosting major acquisitions by top-tier medtechs. Companies that reported after the calendar year-end were the first to see the consequences of the pandemic on their annual figures.

The disruptive medtech M&A of recent years was not matched in the past year for volume, but there were isolated outbreaks of major activity, as shown in our company rankings. 

Medtech Insight recorded 17 merger or acquisition deals in March, a rise from the nine deals recorded last month and in the same period last year. It was a busy month for Boston Scientific, which racked up two acquisitions, paying $460m for urology device maker NxThera and an undisclosed price for endoscopy firm EMcision.

With $1 billion under management, Hong Kong-based private equity firm Ally Bridge Group bagged multiple deals in 2015 including WuXi's $3.3 billion privatization. ABG's CEO Frank Yu talks about pursuing a holistic approach that goes beyond ABG's China roots.